

Study Update

We are pleased to report that all study sites are now set up to recruit into LIBERATE with South Health Campus and Kingston Health Sciences most recently joining the study.

We thank all of our study sites for their continued efforts as we work our way toward a total enrollment of 200 subjects by year-end.

Funding Application

We have submitted an application for the fall CIHR Project Grant funding competition with the aim of expanding the study to additional Canadian and international sites.


The results of the competition will be announced January/February 2025.

LIBERATE NEWSLETTER


Volume 3/Issue 2
November 2024

Image removed

Recruitment by site



LIBERATE Recruitment Targets



FAQs

Q. A patient we're screening was on Norepinephrine 0.5 mcg/kg/min which was the peak dose and for the past couple of hours it is at 0.48 mcg/kg/min. The patient has been on Vasopressin 0.04 u/min. Does this patient qualify for the study?

A. It appears the maximum dose was norepinephrine 0.5 mcg/kg/min and vasopressin 0.04 u/min. As they are on 0.48 mcg/kg/min and 0.04 u/min, respectively, they are now less than the peak. If they are still within 24 hours of the peak dose, they would qualify.

Q. Our patient's vasopressor was stopped and then 24 hours after that, IP administration was stopped. The vasopressor was restarted 48 hours later. Should the IP be restarted?

A. The study IP should not be restarted. On the Outcomes CRF please indicate 'yes' to the question "vasopressors re-initiated over 24 hours after cessation".

Q. We have a patient who was on vasopressors over the weekend, then off for a day or two. They were just restarted on vasopressors yesterday. May we start the clock again for potential enrolment?

A. Yes, the clock may start again for potential enrolment. There is no limit to the number of times a patient may be screened.

Oleksa Rewa, Principal Investigator:

rewa@ualberta.ca

Dawn Opgenorth, Project Manager:

dawno@ualberta.ca

Study website:

<https://www.ualberta.ca/critical-care/research/liberate/index.html>

The LIBERATE Study is supported by the Canadian Critical Care Trials Group, the Alberta Clinical Care Strategic Clinical Network, and the University Hospital Foundation Medical Research and Kaye Fund